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Effects of Perioperative Iloprost on Patency of Femorodistal 
Bypass Grafts 
The Iloprost Bypass International Study Group 
Objective: To investigate the effect of a 3 day perioperative iloprost regimen on the patency of femorodistal bypass 
grafts. 
Design: Prospective, randomised, placebo-controlled study. 
Setting: Twenty-one specialised vascular surgical centres in Northern Europe. 
Subjects and treatments: Preoperatively 528 patients undergoing femorodistal bypass urgery were randomised to receive 
either iloprost or placebo intravenously at the beginning of the operation and in three daily 6 h infusions postoperatively 
with an intragraft injection given on completion of the bypass procedure. 
Chief outcome measures: Patency, surgical interventions and clinical outcome were recorded in all cases for 12 months 
after bypass. 
Results: Five hundred and seventeen patients received a bypass as planned and were evaluable. The graft material was vein 
in 424 cases (82%) and prosthetic or partly prosthetic in 92 (18%). Overall primary patency rates at 12 months were 
52.0% for vein grafts and 45.1% for prosthetic grafts (p = 0.25). The effect of iloprost on primary patency was not 
statistically significant at 12 months in either vein or prosthetic grafts, but an early effect of improved patency in prosthetic 
grafts was seen over the first 3 days. Other results at the end of follow-up were similar in both treatments groups: 105 
patients (20.3%) had been amputated, a further 85(16.4%) had died and 78 (15.1%) were still suffering from rest pain or 
trophic lesions. Two hundred and thirty-eight patients (46.0%) were alive with both legs and either no symptoms or only 
intermittent claudication after 12 months. 
Conclusions: In the setting of this multicentre trial no long-term benefits from the use of a 3 day iloprost regimen were 
demonstrated. Surprisingly small differences were found between the outcomes of vein and prosthetic femorodistal bypass 
grafts. 
Key Words: Femorodistal bypass; Controlled randomised trial, Ilopros# Patency; Clinical outcome. 
Introduction 
Successful bypass urgery from the femoral arteries to 
the crural vessels avoids the need for amputation i  
many cases of limb threatening ischaemia. Despite 
many improvements in techniques ince they were 
first introduced, these procedures continue to suffer 
from a high failure rate. ~ Vein grafts are generally 
considered to be superior to prosthetic materials. 
Other factors affecting the outcome include the length 
of the bypass, the small diameter of the vessel 
available for distal anastomosis, restricted run-off and 
the often poor general health of the patients. Pub- 
lished results from single centres how widely varying 
results, probably due to differences in patient selection 
and surgical technique. The general applicability of 
new techniques and adjuvant therapies therefore 
needs to be tested in large, well controlled, multicentre 
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studies before their widespread use can be 
advocated. 
Current adjuvant pharmacotherapy aimed at 
improving the outcome of distal bypass surgery 
usually consists of antithrombotic agents such as 
aspirin or oral anticoagulants. There have, however, 
been few large, controlled, multicentre trials of these 
drugs. A recent meta-analysis ndicated a role for 
platelet inhibitors in peripheral arterial reconstruction 
in general, 2 but their efficacy in improving distal 
bypass patency remains to be established. 3 
The prostacyclin analogue, iloprost, has been exten- 
sively investigated in patients with critical limb 
ischaemia nd results indicate that it can reduce the 
likelihood of amputation. 4 Small single centre studies 
with iloprost in distal bypass urgery have shown that 
intragraft injection at the end of the bypass procedure 
can reduce the distal resistance and produce a sus- 
tained increase in blood flow through femorodistal 
vein grafts in the early postoperative period. 5 There 
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was also evidence that this might be translated into a 
beneficial effect on bypass patency. 6 
The purpose of this study was to investigate the 
effects of iloprost given for 3 days perioperatively on 
graft patency up to 12 months in vein and prosthetic 
femorodistal bypasses. 
Material and Methods 
The design of the study was a double blind, rando- 
mised, prospective, multicentre trial. Patients were 
recruited from 1990 to 1992 in 21 vascular surgical 
centres from six countries in Northern Europe (Den- 
mark Ireland, The Netherlands, Norway, Sweden and 
the United Kingdom). Data collection was monitored 
from a co-ordinating centre and validated by reference 
to original data sources uch as hospital records. The 
protocol was approved by the appropriate Ethics 
Committee for each of the participating centres. 
It was planned to study patients undergoing bypass 
surgery for critical ischaemia with the proximal 
anastomosis above the knee and the distal anastomo~ 
sis to the tibioperoneal trunk, the anterior tibial, 
posterior tibial or peroneal artery. Critical ischaemia 
was defined as: (1) the presence of trophic lesions or 
(2) persistent rest pain requiring analgesia for at least 
2 weeks plus an ankle pressure of less than 50 mmHg, 
except in the case of diabetics with calcified arteries 
where absent palpable foot pulses were taken as 
evidence of severe vascular disease7 
Specific criteria for exclusion were known bleeding 
disorders, active gastrointestinal bleeding, recent cer- 
ebrovascular ccident. 
Informed consent was obtained and patients were 
randomised to receive either iloprost or placebo. 
Randomisation was stratified by centre. Iloprost or 
placebo was diluted into 500ml of physiological 
saline. The treatment consisted of an intravenous 
infusion up to 20 ml/h for I h starting after induction 
of anesthesia, n injection of 15 ml into the proximal 
end of the bypass graft on completion of the proce- 
dure but before skin closure, a 6h infusion up to 
20 ml/h starting I h after the end of the operation and 
a further 6 h intravenous infusion on each of the two 
following days up to a maximum of 40ml/h. The 
infusion rates of 20 and 40 ml/h were equivalent in the 
average patient o iloprost doses of 1.0 and 2.0 ng/kg/  
min and the intragraft injection of 15 ml was equiva- 
lent to a dose of 3000 ng iloprost. Systemic haemody- 
namics and side effects were monitored during 
intravenous infusions and the infusion rate reduced 
when indicated. 
Heparin, oral anticoagulants and dextrans were 
used both during and after treatment with the study 
substance according to each centre's policy. The use of 
aspirin and other platelet aggregation i hibitors was 
not permitted uring the 3 days of study treatment, 
but was allowed thereafter according to the policy of 
each individual centre. Peripheral vasodilators and 
other drugs for the treatment of critical ischaemia 
were not allowed during the study. All concomitant 
medications were recorded. 
Demographic data, past medical history, risk fac- 
tors, clinical status, ankle and brachial Doppler pres- 
sures were recorded preoperatively. Ankle-brachial 
pressure index (ABPI) was calculated. Angiographic 
run-off was calculated using a method which takes 
into account both the number and state of the vessels 
distal to the graft. 8 The run-off was scored between 1
and 10 where 1 represents excellent outflow and 10 
represents no outflow. Technical details of the opera- 
tion included the type of anaesthesia, location of the 
anastomoses, graft length and diameter, graft material 
concomitant procedures and complications. 
Postoperative follow-up on all patients was 12 
months. Graft patenc~ clinical symptoms and Dop- 
pler pressures were recorded at 2 days, 3 days, 14 days 
(or discharge if sooner), 3 months and 12 months. 
Assessments of graft patency at 6 weeks and 6 months 
and graft surveillance by Duplex ultrasound at all 
time-points were optional. Graft stenoses were con- 
sidered to be clinically significant if the ratio of blood 
flow velocity at the point of greatest stenosis was at 
least twice that at another point within 2 cm. Further 
vascular interventions in the relevant leg including 
amputations was recorded whenever they occurred. 
Primary patency was defined as patency of the graft 
without any further intervention after skin closure in 
the initial bypass operation. Further intervention 
without the graft having first occluded led to a 
definition of assisted primary patency and successful 
intervention after graft occlusion to secondary 
patency. 
Statistical considerations 
The study sample size was chosen based on the ability 
to detect a difference of 13% in patency rates between 
iloprost and placebo. Literature review prior to the 
start of the study suggested primary patency in vein 
grafts in the control group to be 75%, which resulted in 
a hypothesised 88% patency rate for the iloprost 
group. Calculations were based on a test of independ- 
ent proportions performed with ~ = 0.05 and ~ = 0.10. 
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A total of 221 evaluable patients were required per 
treatment group. 
Statistical analyses were performed on all available 
data for all patients (intention to treat) for whom graft 
patency could be assessed. Patients were divided into 
two groups for the analysis of patency data: those 
receiving vein grafts and those receiving rafts partly 
or wholly consisting of prosthetic material. Bypass 
patency and amputation curves were based on 
Kaplan-Meyer estimates, and overall differences 
between pairs of curves were compared using log- 
rank tests. Differences in patency at individual time 
points were compared using uncorrected Chi-square 
tests. Chi-square tests were also used for all other 
categorical data. For continuous variables (e.g. ABPI), 
rank-sum tests were used to compare treatment 
differences and results are expressed as mean + S.D.. 
Results 
Patients 
Over the 2 year period, 528 patients were randomised 
into the study. Eleven were excluded after randomisa- 
tion: eight were found to be unsuitable for bypass on 
commencement of the operation and three received 
treatment, but had no data recorded. This resulted in 
517 patients being available for analysis of bypass 
patency, 267 randomised to iloprost and 250 to the 
placebo group. The number of Cases entered by 
individual centres varied between 1 and 100, but no 
centre contributed more than 20% of the total. 
The 517 patients consisted of 317 males and 199 
women (and 1 unclassified) with a mean age of 71.2 
years. Female patients comprised 110 (41.2%) of the 
iloprost group and 90 (36.0%) of the placebo group. 
The distribution of the patients' preoperative charac- 
teristics shows (Table 1) that the groups were gen- 
erally well matched. The patients' arterial disease was 
classified as Fontaine stage III (34%) or Fontaine stage 
Table 1. Preoperative characteristics 
Number (%) of patients 
Iloprost 
(n=267) 
Placebo All patients 
(n=250) (n=517) 
Hypertension 60 (22.5) 63 (25.2) 123 (23.8) 
Diabetes mellitus 99 (37.1) 85 (34.0) 184 (35.6) 
Known hyperlipidaemia 16 (6.0) 18 (7.2) 34 (6.6) 
Evidence of cardiac failure 25 (9.4) 18 (7.2) 43 (8.3) 
Current smoker 89 (33.3) 94 (37.6) 183 (35.4) 
Previous myocardial infarct 58 (21.7) 59 (23.6) 117 (22.6) 
Previous cerebral infarct 31 (11.6) 26 (10.4) 57 (11.0) 
IV (65.2%) in all but four cases. Rest pain was reported 
in 499 patients (96.5%), but only 406 (78.5%) were 
receiving any analgesia. There was a greater propor- 
tion of patients with both ulcers and necroses in the 
iloprost group than in the placebo group: 85 patients 
(31.8%) compared to 55 (22.0%). Arterial pressures 
were similar in the two groups: the mean ankle 
pressure recorded in the relevant leg was 56.2 mmHg 
with 188 patients (36.4%) having a pressure of 
< 50 mmHg and the mean ABPI was 0.37 with 462 
cases (89.3%) being a 0.6. Angiographic run off scores 
in the two groups were similar. 
Surgical procedures 
The duration of surgery was a mean of 4.0 h (range 
2.0-8.5) in all patients and general anaesthesia with or 
without epidural was used in 287 cases (55.5%), 
epidural alone in 198 (38.3%) and intradural or local 
nerve blocks in the remainder. The proximal anasto- 
mosis was most commonly made to the common 
femoral arter3~ femoral bifurcation or proximal super- 
ficial femoral artery (438 cases (84.8%)) and only rarely 
to the mid superficial femoral artery or above-knee 
popliteal artery. The distal anastomoses were distrib- 
uted evenly between the anterior tibial, posterior tibial 
and peroneal arteries in both treatment groups with a 
smaller proportion on the tibioperoneal trunk (Table 
2). These anastomoses were also evenly distributed 
between the upper, mid and lower thirds of the calf 
vessels. Vein grafts, including composite grafts from 
two pieces of vein, were used in 424 cases (82%) and 
prosthetic or prosthetic-vein composite grafts in 92 
(18%). A greater proportion of the prosthetic grafts 
were performed in the iloprost group (Table 3). The 
mean graft length was similar in both treatment 
groups, but the minimum graft diameters were not as 
evenly distributed and were significantly smaller in 
the iloprost group than the placebo group: 3.71 + 1.02 
and 4.00 + 1.39 respectively. Concomitant procedures 
Table 2. Distal anastomosis 
Number (%) of patients 
lloprost 
(n=267) 
Placebo All patients 
(n=250) (n=517) 
Popliteal 7 (2.6) 
Tibioperoneal trunk 20 (7.5) 
Anterior tibial 94 (35.2) 
Posterior tibial 75 (28.1) 
Peroneal 70 (26.2) 
Dorsalis pedis 1 (0.4) 
2 (0.8) 9 (1.7) 
24 (9.6) 44 (8.5) 
85 (34.0) 179 (34.6) 
69 (27.6) 144 (27.9) 
69 (27.6) 139 (26.9) 
1 (0.4) 2 (0.4) 
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Table 3. Graft material 
Number (%) of patients 
Iloprost Placebo All patients 
(n=267) (n=250) (n=517) 
In situ saphenous vein 141 (52.8) 151 (60.4) 292 (56.5) 
Reversed saphenous vein 47 (17.6) 43 (17.2) 90 (17.4) 
PTFE 39 (14.6) 23 (9.2) 62 (12.0) 
Other prosthetic 0 (0) 1 (0.4) 1 (0.2) 
Vein-prosthetic composite 18 (6.7) 11 (4.4) 29 (5.6) 
Vein-vein composite 21 (7.9) 21 (8.4) 42 (8.1) 
Unclassified 1 (0.4) 0 (0) 1 (0.2) 
were performed in similar numbers of cases in each 
treatment group: endarterectomy in 89 (17.2%) and 
profundaplasty in 20 (3.9%). Intra-operative graft 
revision was necessary in 44 operations (8.5 %), usually 
at the distal anastomosis, and intraoperative t chnical 
complications were reported in a total of 67 cases 
(13.0%): iloprost 32 cases (12.0%) and placebo 35 cases 
(14.0%). 
Treatment and adverse vents 
The infusion of study medication at the beginning of 
the operation was given to 506 patients (97.9%) and 
the intragraft injection of iloprost or placebo to 498 
(96.4%). Postoperatively 222 iloprost patients (83.1%) 
and 212 placebo patients (84.8%) received all three 
intravenous infusions. Only six iloprost patients 
(2.2%) and six placebo patients (2.4%) did not receive 
any postoperative treatment with the study medica- 
tion. Significantly more iloprost patients had side- 
effects during the operation, most commonly hypoten- 
sion: iloprost 39 patients (14.6%) and placebo 10 
patients (4.0%) (p < 0.001). There were no significant 
differences in any other intraoperative vents. In 
addition, hypotension, ausea, headache, flushing and 
injection site reactions were all significantly more 
common postoperatively with iloprost than placebo. 
One hundred and fifty-four iloprost cases (57.7%) 
compared to 93 placebo cases (37.2%) reported some 
kind of adverse experience postoperatively 
(p > 0.001). However, these were not serious enough 
to result in more iloprost than placebo patients 
discontinuing infusions. During the first 14 days 
postoperatively the incidence of major adverse vents 
such as myocardial infarction, cerebrovascular cci- 
dent and death from any cause was not significantly 
different in the two treatment groups. The incidences 
for iloprost and placebo respectively were: myocardial 
infarction 10 (3.7%) and 11 (4.4%), cerebrovascular 
accident three (1.1%) and two (0.8%), death from any 
cause nine (3.4%) and six (2.4%). 
Bypass patency and postoperative management 
There was no difference in primary patencies of the 
vein grafts between the groups (p -- 0.81) (Fig. 1). The 
difference for secondary patency was never more than 
4.4% and was not statistically significant over the 12 
months (p = 0.42). The difference in patency rates 
between the treatment groups in the patients receiving 
prosthetic grafts was greater than in those having vein 
grafts. The primary patency curves for prosthetic 
grafts showed a significant difference at the end of the 
three day treatment period, 94.5% iloprost compared 
to 74.3% placebo (p < 0.01) (Fig. 2), but the differences 
were not significant over the whole 12 month follow- 
up period (p = 0.49). The secondary patency curves 
showed similar results (p = 0.77). 
Comparison of primary patency curves from the 
different categories of graft material shown in Table 3 
revealed significant differences (p = 0.013) with 
reversed vein grafts achieving the best results at 12 
months (60.6%) and PTFE grafts the worst (43.7%). 
However, comparison of primary patency curves for 
all vein grafts with all prosthetic grafts (Fig. 3) did not 
show a statistically significant difference (p = 0.25). 
Secondary patency rates over 12 months were sig- 
nificantly higher for vein grafts than prosthetic grafts 
(p = 0.047). Within the prosthetic group there was no 
consistent difference between the results obtained 
with prosthetic-vein composite grafts and with pure 
PTFE grafts. 
Graft surveillance by Duplex ultrasound was per- 
formed on 320 of the patients in this series at some 
stage during the study. Overall 66 patients (20.6%) had 
at least one clinically significant graft stenosis 
detected: iloprost 39 patients (23.6%) and placebo 43 
patients (17.3%) (p = 0.16). Some type of surgical 
intervention i the relevant limb other than amputa- 
tion was performed in 84 patients receiving iloprost 
(31.6%) and 78 of those receiving placebo (31.2%). 
Local thrombolytic treatment was used in eight of the 
iloprost cases (2.9%) and 13 placebo cases (5.1%). 
Additional antithrombotic drugs were allowed post- 
operatively and the use of these did not differ 
significantly in the two treatment groups (Table 4). 
Clinical outcome 
The limb salvage curves were similar in the two 
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treatment groups for both vein and prosthetic grafts 
(Fig. 4 and 5). At the end of the 12 month follow-up 
the limb salvage rates for iloprost and placebo 
respectively were 81.8% and 80.5% for vein grafts and 
73.7% and 71.4% for prosthetic grafts. The overall 
figures for the different materials were 81.1% for vein 
grafts and 72.8% for prosthetic grafts. Mean ankle 
systolic pressures at 12 months in surviving limbs 
with patent grafts were iloprost 145 + 50 mmHg and 
placebo 136 + 45 mmHg (p = 0.09). Mean ABPI at 12 
months in these patients were iloprost 0.92 _+ 0.28 and 
placebo 0.86 ___ 0.25 (p = 0.09). 
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The clinical status of the patients at the end of the 
follow-up was not statistically significant between the 
two treatment groups. Overall 238 (46.0%) of the 
patients entering the study were classified as Fontaine 
stage I or stage II 12 months later, 78 patients (15.1%) 
were still in Fontaine stage III or stage IV, 105 (20.3%) 
had been amputated and a further 85 patients (16.4%) 
had died. Just 11 patients (2.2%) were not fully 
documented at the end of follow-up. 
Discuss ion  
The success of a femorodistal bypass operation for 
severe ischaemia can be judged in terms of bypass 
patency, avoidance of amputation and resolution of 
the clinical symptoms. The first two of these criteria 
are those which are usually reported in the literature. 
Patency rates reported for femorocrural bypass have 
Table 4. Additional postoperative antithrombotic medication 
% of patients 
Iloprost Placebo All patients 
Medication (n=267) (n=250) (n=517) 
Aspirin 25.1 30.8 27.9 
Oral anticoagulants 36.7 36.8 36.8 
Dextrans 25.1 31.2 28.0 
improved over time, but still range for example from 
45% in prosthetic grafts 9to 87% in vein grafts 1° at 12 
months. It is often difficult to know if results being 
quoted are true primary patency rates or include 
assisted primary patency or refer to secondary 
patency. The majority of reports come from single 
centres and differences in patient selection, surgical 
technique and follow-up also contribute to the varying 
results reported. However, a consistent feature of 
published series is that much better results are 
obtained with vein grafts than with prosthetics. A
surprising feature of the primary patency rates in this 
study, therefore, was that the difference between the 
two materials was only 7.0% at 12 months and not 
statistically significant. Most reported series quote 
higher patency rates in vein grafts, but the inclusion of 
over 400 such procedures in this study from over 20 
specialised vascular centres leads to the conclusion 
that these results are representative of the general 
situation. The findings are lent additional weight by 
the fact that the study was independently monitored 
and produced 12 month follow-up data on over 97% 
of the cases operated. 
All of the patients included in this trial were 
deemed by the operating surgeons to be critical. It is 
clear that all of the patients had severe lower limb 
ischaemia, but interesting to note that almost half of 
the patients failed to comply with the European 
consensus for the definition of critical ischaemia. 7 This 
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Any effect of the 3 day iloprost regimen on the vein 
graft patency was minimal and was not demonstrated 
in this study. There did appear to be an effect of 
iloprost on the early patency of prosthetic grafts 
during the treatment period, but this was not statisti- 
cally significant over the whole follow-up, possibly 
due to the short duration of iloprost therapy and the 
smaller number of prosthetic grafts performed. 
The limb salvage rate after bypass urgery was also 
not significantly influenced by iloprost reatment. The 
overall major amputation rate of 20.3% at 12 months is 
comparable to many published studies, 11 but should 
probably be considered in the context of the overall 
clinical outcome. In addition to the patients who 
underwent amputation, 16.4% died in the course of 
the follow up and 15.1% were still suffering from 
severe ischaemic symptoms at 12 months. Less than 
half of the patients had an improved clinical status 12 
months after the operation. Clinical outcome in 
patients undergoing bypass urgery is rarely reported 
and assuming that these results are typical it suggests 
that bypass patency does not always result in an 
improved clinical outcome. The results concerning 
mortality, amputation rate and clinical outcome are 
very similar to recent results from a population based 
vascular surgical registry supporting the general- 
isability of the findings. 12 
Previous studies with iloprost in this indication 
have shown dramatic effects on distal resistance and 
graft blood flow s'13 and evidence of a beneficial effect 
on bypass patency. 6 There are a number of differences 
between the earlier studies and this latest study. The 
most striking one is that this study is much larger and 
in this respect more likely to reflect results when 
iloprost is used generally. However, all of the studies 
were placebo controlled and double blind and there 
are other factors which may influence this conclusion. 
The treatment regimen in the earlier studies consisted 
of only a single intragraft injection of iloprost, whereas 
in this study three postoperative intravenous infu- 
sions were also given. It had been expected that the 
addition of postoperative infusions would confer an 
additional benefit due to the improvement of tissue 
perfusion and the antithrombotic effect of iloprost, but 
it is also conceivable that a tendency to lower the 
systemic blood pressure resulted in a steal phenome- 
non in some patients masking the benefit derived in 
other cases. Analysis of early patency by decreased 
blood pressure did not support his argument, how- 
ever. The other major difference in the ~tudy designs 
was that the earlier studies were performed in single 
centres with consistent policies on patient selection, 
surgical technique and anaesthetic regimen, whereas 
this study was performed in 21 vascular surgical 
centres. 
Although all centres adhered to a strict study 
protocol with criteria for patient inclusion in the study, 
there was no way of standardising the original 
decision that the patient was suitable for femorodistal 
bypass. It is also inevitable that there were differences 
in preferred surgical techniques and concomitant 
medications. However, the various techniques were 
generally evenly distributed between the two treat- 
ment groups and there are currently no known 
interactions between iloprost and other concomitant 
medications used in this study. The two groups were 
unbalanced in only three respects which might have 
prejudiced the outcome of the trial: the proportion of 
females, vein graft diameter and use of aspirin. Each 
of these factors were statistically associated with graft 
patency and the distribution of each favoured the 
placebo group, but not significantly so. 
It can be concluded, therefore, that in this study no 
beneficial effect of iloprost was shown in patients 
receiving vein grafts. Although not the primary 
objective of the study, a reduction in prosthetic graft 
failure by iloprost was shown in the immediate 
postoperative period offering the possibility that a 
longer term benefit might be shown in these cases if 
the duration of treatment could be extended. 
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The Iloprost Bypass International Study Group 
Denmark: 
Lorentzen JE, Schroeder TV, Nielsen OM (Rigshospi- 
tal, Copenhagen) 
Great Britain: 
Simms MH, Thomson IA, Garnham A (Selly Oak 
Hospital, Birmingham); Baird RN, Lamont PM, Ten- 
nant SGW (Bristol Royal Infirmar~ Bristol); Harris PL, 
Nott D (Broadgreen Hospital, Liverpool); Wolfe JHN, 
Cheshire N (St. Mary's Hospital London); Taylor RS, 
Dormandy JA (St. George's Hospital, London), McFar- 
land RJ (Epsom District Hospital, Epsom); Lambert D, 
Redwood N (Royal Victoria Infirmar~ Newcastle); 
Horrocks M, Horrocks EH (Royal United Hospital 
Bath) 
Ireland: 
Shanik G, Colgan MP, Moore D (St. James's Hospital 
Dublin) 
Netherlands: 
Moll FL, Rijbroek A (Medisch Centrum Alkmaar, 
Alkmaar); Buth J, de Gier P, Stam L (Catharina 
Ziekenhuis, Eindhoven); Eikelboom BC, van de 
Pavoordt H (St. Antonius Ziekenhuis, Nieuwegein); 
van Urk H, van Dijk L (Dijkzigt Ziekenhuis, 
Rotterdam) 
Norway: 
Myhre HO, Saether O, Urnes O (University Hospital, 
Trondheim); Fossdal JE, Nordang E (Sentralsjukhuset i 
RogalanG Stavanger) 
Sweden: 
Norgren L, Jonung T, Ribbe E, Th6rne J (University 
Hospital, Lund); Konrad P, T6rngren S (S6dersjukhu- 
set, Stockholm); Bergqvist D, Eriksson I, Karacagil S 
(Akademiska Sjukhuset, Uppsala); Lundell A (All- 
m~nna Sjukhuset, Malm6); Swedenborg JE, Tako- 
lander R (Karolinska Hospital, Stockholm) 
Co-ordination: 
Watson HR, Tompkins SP (Cardiovascular Clinical 
Development, Schering Health Care Ltd, Burgess Hill, 
UK) 
Statistics: 
Lehr RG (Biostatistics Department, Berlex Laborato- 
ries Inc., Wayne, NJ, US) 
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